Sell Portola Pharmaceuticals For a 45% Win!
Posted by Lance Jepsen on April 10, 2017 5:10 PM
Tags: Andexanet alfa, Anticoagulant, Biopharmaceutical, Biotechnology, Bristol-Myers Squibb, Clinical trial, Disease, Drug, European Medicines Agency, Food and Drug Administration, Marketing Authorization Application, Pfizer, Pharmaceutical drug, Pharmacology, Portola Pharmaceuticals, Prescription Drug User Fee Act, Thrombosis, Venous thrombosis
April 10, 2017: Sell Portola Pharmaceuticals for a 45% win and congratulations if you made money on the trade.
December 27, 2016: Portola Pharmaceuticals price target raised to $29 from $20 at Credit Suisse, reiterates Neutral rating.
December 26, 2016: Biotechnology firm Portola Pharmaceuticals had revenue of $12.1 million in 2015. For 2016, revenue is on track to more than double to $26.2 million.
December 23, 2016: Portola Pharmaceuticals reports that the FDA accepts NDA for priority review for betrixaban, a prophylaxis of venous thromboembolism (VTE) Granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six months from the standard review period of 10 months. The application for betrixaban, an FDA-designated Fast Track investigational drug, was deemed sufficiently complete to permit a substantive review and has been given a Prescription Drug User Fee Act (PDUFA) action date of June 24, 2017. Additionally, Portola announced that the European Medicines Agency (EMA) had validated its Marketing Authorization Application (MAA) for betrixaban for extended-duration prophylaxis of VTE in adults with acute medical illness and risk factors for VTE. The EMAs Committee for Medicinal Products for Human Use (CHMP) is reviewing the application under a standard 210-day review period.
December 19, 2016: Portola Pharmaceuticals announced it had signed a $50 million loan agreement with Bristol-Myers Squibb Company and Pfizer Inc. that provides additional funding toward development and clinical studies of AndexXa (andexanet alfa), an investigational compound that is a potential antidote for Factor Xa inhibitors. Under the terms of the agreement, Bristol-Myers Squibb and Pfizer will each loan Portola $25 million. The principal and interest will be repaid primarily through royalties on AndexXa commercial sales. No shares, warrants, options or other equity components were or will be issued in connection with the loan. The non-secured loan does not involve any transfer of patent ownership or licenses.
December 15, 2016: Heavy call activity detected in Portola Pharmaceuticals of 1500 Jan 20 calls traded at $1.15.
Portola Pharmaceuticals Stock Chart
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases.
Latest posts by Lance Jepsen (see all)
- S&P 500 Index Does Breakout, 2500 Next - May 28, 2017
- IMAX Theaters Goes Into Virtual Reality as M&A Talk Picks Up - May 28, 2017
- How High Bitcoin Go 2017, Many Say $10,000 - May 28, 2017
Active Stock Picks
- Amgen Expands Collaboration with Novartis for Erenumab in…
- Biogen Acquires Remedy Pharmaceuticals’ Late-Stage Drug…
- Sell Nektar Therapeutics For a 35% Win
- Ionis Pharmaceuticals Crushes Earnings and Revenue Estimates
- Wells Fargo Gives Buy On Juno One Day, Downgrades the Next!
- Bellicum Pharmaceuticals Updates On Clinical BP-004 Study